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Substance use disorderWe aimed to examine pharmacologic, demographic and medical comorbidity risk factors for opioid-related
mortality among patients currently receiving methadone for an opioid use disorder. We conducted a
population-based, nested case-control study linking healthcare and coroner's records in Ontario, Canada, from
January 31, 1994 to December 31, 2010. We included social assistance recipients receiving methadone for an
opioid use disorder. Within this group, cases were those who died of opioid-related causes. For each case, we
identiﬁed up to 5 controls matched on calendar quarter. The primary analysis examined the association between
use of psychotropic drugs (benzodiazepines, antidepressants or antipsychotics) and opioid-related mortality.
Secondary analyses examined the associations between baseline characteristics, health service utilization,
comorbidities and opioid-relatedmortality. Among 43,545 patients receivingmethadone for an opioid use disor-
der, we identiﬁed 175 (0.4%) opioid-related deaths, along with 873matched controls. Psychotropic drug usewas
associated with a two fold increased risk of opioid-related death (adjusted odds ratio (OR) 2.0; 95% conﬁdence
interval (CI) 1.2 to 3.5). Speciﬁcally, benzodiazepines (adjusted OR 1.6; 95% CI 1.1 to 2.5) and antipsychotics
(adjusted OR 2.3; 95% CI 1.5 to 3.5) were independently associated with opioid-related death. Other associated
factors included chronic lung disease (adjusted OR 1.7; 95% CI 1.2 to 2.6), an alcohol use disorder (adjusted OR
1.9; 95% CI 1.2 to 3.2),mood disorders (adjustedOR1.8; 95% CI 1.0 to 3.2), and a history of heart disease (adjusted
OR 5.3; 95% CI 2.0 to 14.0). Psychotropic drug use is associated with opioid-related death in patients receiving
methadone. Mindfulness of these factors may reduce the risk of death among methadone recipients.-06, Toronto, O
6048.
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In patients undergoing treatment for opioid use disorders, meth-
adone therapy is associated with several improved outcomes, in-
cluding retention in drug treatment as well as reduced opioid use,
and some observational studies have observed reductions in all-
cause mortality and risk of death from overdose (Esteban et al.,
2003; Gibson et al., 2008; Huang & Lee, 2013; Langendam, van
Brussel, Coutinho, & van Ameijden, 2001; Mattick, Breen, Kimber, &
Davoli, 2009; Perry et al., 2013; Schwartz et al., 2013). On the basis
of its effectiveness, theWorld Health Organization addedmethadonethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
31P. Leece et al. / Journal of Substance Abuse Treatment 57 (2015) 30–35to its list of essential medicines in 2005. It is included on the comple-
mentary list of “essential medicines for priority diseases”, for which
specialist care is needed (World Health Organization, 2005). As
prescription opioid use continues to increase (Dhalla et al., 2009),
so has opioid misuse and the demand for treatment (Fischer,
Nakamura, Rush, Rehm, & Urbanoski, 2010). Consequently, the num-
ber of patients treatedwithmethadone has increased dramatically in
North America over the past 10 years (Luce & Strike, 2011; Substance
Abuse and Mental Health Services Administration Center for Behav-
ioral Health Statistics & Quality, 2013).
Many challenges accompany methadone therapy, including multi-
ple drug interactions and the risk of fatal QT prolongation (Chou,
Weimer, & Dana, 2014; Kapur, Hutson, Chibber, Luk, & Selby, 2011).
Drug-related deaths are common among patients on methadone
therapy, as are other medical causes and trauma (Clausen, Waal,
Thoresen, & Gossop, 2009; Zador & Sunjic, 2000). Individuals on
methadone therapy have a higher risk of death during periods of induc-
tion and discontinuation (Caplehorn & Drummer, 1999; Clausen et al.,
2009; Degenhardt et al., 2009; Srivastava & Kahan, 2006; Zador & Sunjic,
2000; Zanis & Woody, 1998). Additionally, some evidence suggests an
association between drug-related death and psychiatric disorders,
during or after cessation of methadone treatment (Cousins et al.,
2011; Zanis & Woody, 1998).
Methadone prescribing is highly regulated, and patients are closely
monitored due to the associated risks of treatment. Clinical practice
guidelines identify factors that may increase the risk of methadone
toxicity (Chou et al., 2014; Hillier, 2011). Most methadone-associated
deaths involve methadone obtained from non-prescription sources or
methadone prescribed for pain (Heinemann, Iwersen-Bergmann,
Stein, Schmoldt, & Püschel, 2000; Paulozzi et al., 2009; Weimer,
Korthuis, Behonick, & Wunsch, 2011), but safety concerns persist in
light of the growing number of methadone-related deaths (US Depart-
ment of Health and Services, 2010).
Previous studies have examined various risk factors for overdose-
related death among patients in drug treatment programs, including
street drug use, demographic, and comorbidities (HIV, hepatitis status,
and mental and physical health scores) (Brådvik, Berglund, Frank,
Lindgren, & Löwenhielm, 2009; Brugal et al., 2005; Gossop, Stewart,
Treacy, & Marsden, 2002; Peles, Schreiber, & Adelson, 2010). Others
have examined cardiac mortality among subjects whose methadone
levels precluded drug toxicity as the cause of death (Chugh et al.,
2008). Still others have explored the role of systemic disease (Darke,
Kaye, & Duﬂou, 2006) and medical and psychiatric comorbidity risk
factors for all-cause mortality among individuals who entered metha-
done maintenance treatment (Huang & Lee, 2013).
However, important gaps remain in the literature related to predic-
tors of opioid-related deaths among patients currently in methadone
maintenance treatment. Most studies in this area do not clearly differ-
entiate among people who enter methadone therapy rather than drug
treatment more generally (Brådvik et al., 2009; Gossop et al., 2002),
those who remain on methadone therapy or those who discontinue
(Brugal et al., 2005), those who die while using prescribed or non-
prescribed methadone treatment (Chugh et al., 2008; Darke et al.,
2006), or those who die of an opioid- or non-opioid overdose (Huang
& Lee, 2013; Peles et al., 2010).
Methadone prescribers are advised to use caution when treating
patients who use benzodiazepines or alcohol, as well as those who
have lung disease. However, the extent to which other co-morbid con-
ditions or concurrent prescriptions inﬂuence the risk of opioid-related
death during methadone therapy is less well understood (Chan, Stajic,
Marker, Hoffman, & Nelson, 2006; Cousins et al., 2011; McCowan,
Kidd, & Fahey, 2009; Pilgrim, McDonough, & Drummer, 2013; The
DAWN Report, 2004). Previous studies of the extent to which
psychotropic drugs increase the risk of drug-related death in metha-
done recipients used a restrictive case deﬁnition of “deaths caused
directly by the consumption of one or more illegal drugs” (Cousinset al., 2011; EuropeanMonitoring Centre for Drugs and Drug Addiction,
2009; McCowan et al., 2009). We examined the association between
psychotropic drug use, among other factors, and opioid-related
mortality in patients receiving methadone treatment for an opioid
use disorder.
2. Material and methods
2.1. Setting and design
We conducted a nested case-control study of Ontario residents be-
tween January 31, 1994 and December 31, 2010. These individuals
had universal access to hospital care, physicians' services, and prescrip-
tion drug coverage. The study was approved by the Research Ethics
Board of Sunnybrook Health Sciences Centre, Toronto, Ontario.
2.2. Sources of data
We identiﬁed prescription records using the Ontario Drug Beneﬁt
(ODB) Database, which contains comprehensive records of prescription
medications dispensed to Ontarianswhose prescriptions costs are reim-
bursed by the provincial government. In 2006 in Ontario,more than 70%
of methadone recipients were insured under this program (Hart, 2007).
Methadone prescriptions are recorded in the ODB database for each
date methadone was dispensed, regardless of whether doses were ob-
served in a pharmacy. In Ontario, methadone prescribing guidelines
specify that methadone must be dispensed daily for at least the ﬁrst
2 months of treatment (Hillier, 2011). Methadone prescribers undergo
regular mandatory practice audits by the College of Physicians and Sur-
geons of Ontario, and compliance with daily dispensing in the ﬁrst
2 months is extremely high.
Opioid-related deaths were identiﬁed using the records of the Chief
Coroner for Ontario, as done previously (Dhalla et al., 2009; Dhalla,
Mamdani, Gomes, & Juurlink, 2011; Gomes et al., 2011). The investigat-
ing coroner classiﬁed opioid-related deaths as those with toxicologic
ﬁndings of opioid concentrations sufﬁciently high to cause death, or
that a combination of drugs (including at least one opioid present at a
clinically signiﬁcant concentration) resulted in death (Dhalla et al.,
2009). The Canadian Institute for Health Information Discharge Abstract
Database (CIHI-DAD) was used to identify hospitalizations, which con-
tains detailed diagnostic and procedural information regarding all
acute care hospital admissions in the province. We used the Ontario
Health Insurance Plan (OHIP) Database to determine physician billing
claims, including visits to physicians licensed to prescribe methadone
and claims for urine drug screens. Comorbidities were identiﬁed using
the CIHI-DAD, CIHI Same-Day Surgery Database (CIHI-SDS), CIHI Na-
tional Ambulatory Care Reporting System (CIHI-NACRS) and OHIP data-
bases. The Adjusted Clinical Group (ACG) scoring system was used to
measure comorbidity in the preceding year (Weiner, 2003). Demo-
graphic information was obtained from the Registered Persons Data-
base (RPDB). These datasets are linked in an anonymous fashion using
encrypted health insurance numbers, contain little missing information
(Levy, O’Brien, Sellors, Grootendorst, &Willison, 2003), and are routine-
ly used to study drug safety (Juurlink et al., 2004; Juurlink et al., 2009;
Park-Wyllie et al., 2011).
2.3. Identiﬁcation of cases and controls
We deﬁned case patients as those who died of opioid-related causes
within 3 days of receiving a prescription for methadone. The date of
death served as the index date for all analyses. For each case, we
randomly selected up to 5 controls from the population of patients re-
ceiving methadone for an opioid use disorder who did not die of
opioid-related causes on or before the index date. Control subjects
were randomly assigned index dates based on the distribution of case
index dates and matched to case patients on calendar quarter of index
Table 1
Characteristics of cases and controls.
Characteristic Cases
n = 175
Controls
n = 873
Standardized
difference
Median (IQR) age 42 (36–48) 39 (31–45) 0.36
Male, no. (%) 109 (62.3) 543 (62.2) 0.00
Rural, no. (%) 7 (4.0) 72 (8.2) 0.16
Median (IQR) visits to a
methadone prescriber in the
2 months prior
7 (3–11) 7 (4–10) 0.03
Median (IQR) urine drug tests
in the 1 year prior
2 (0–21) 4 (0–27) 0.13
ECG, no. (%)a 77 (44.0) 234 (26.8) 0.38
Initiation of methadone in the
30 days prior to index date,
no. (%)
9 (5.1) ≤5 0.40
John Hopkins ACG, no. (%)a
0–4 45 (25.7) 414 (47.4) 0.44
5–9 66 (37.7) 339 (38.8) 0.02
10–14 54 (30.9) 108 (12.4) 0.52
15–19 10 (5.7) 12 (1.4) 0.30
Diagnoses, no. (%)a
Chronic lung disease 88 (50.3) 251 (28.8) 0.47
Alcohol use disorder 42 (24.0) 73 (8.4) 0.51
Chronic liver disease 40 (22.9) 122 (14.0) 0.25
Heart disease (coronary
artery disease or arrhythmia)
16 (9.1) 9 (1.0) 0.54
Mood disorders 32 (18.3) 53 (6.1) 0.45
Schizophrenia ≤5 7 (0.8) 0.03
Benzodiazepines, antidepressants,
and/or antipsychotics, no. (%)a
154 (88.0) 627 (71.8) 0.37
Benzodiazepines, no. (%) 116 (66.3) 359 (41.1) 0.51
Antidepressants, no. (%) 127 (72.6) 487 (55.8) 0.34
Antipsychotics, no. (%) 84 (48.0) 197 (22.6) 0.59
Opioids, no. (%)a 100 (57.1) 402 (46.0) 0.22
Short-acting oxycodone 0 (0.0) 0 (0.0) 0.00
Long-acting oxycodone 12 (6.9) 68 (7.8) 0.04
Codeine 67 (38.3) 221 (25.3) 0.29
Morphine 13 (7.4) 54 (6.2) 0.05
Hydromorphone 12 (6.9) 35 (4.0) 0.14
Fentanyl 7 (4.0) 12 (1.4) 0.20
Meripidine/Pethidine ≤5 9 (1.0) 0.01
Methadone (for pain) ≤5 ≤5 0.04
Anticonvulsants, no. (%)a 23 (13.1) 43 (4.9) 0.34
Metabolic 12 (6.9) 22 (2.5) 0.25
Sedating 13 (7.4) 23 (2.6) 0.26
QT prolonging drugs, no. (%)a,b 62 (35.4) 224 (25.7) 0.22
No.- number; IQR- interquartile range.
a In the 1 year prior to the index date.
b These included alfuzosin, amiodarone, azithromycin, chloroquine, ciproﬂoxacin,
clarithromycin, crizotinib, cyclobenzaprine, dasatinib, disopyramide, dolasetron, erythro-
mycin, ﬂecainide, granisetron, lapatinib, levoﬂoxacin, ritonavir, moxiﬂoxacin, nilotinib,
norﬂoxacin, ondansetron, pazopanib, pentamidine, procainamide, propafenone, quini-
dine, saquinavir, solifenacin, sotalol, sunitinib, tacrolimus, telithromycin, tetrabenazine.
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excluded patients whose death was classiﬁed as a homicide in the
coroner's database, those receiving palliative care, and those who re-
ceivedmethadone tablets in the preceding 60 days, becausemethadone
tablets are exclusively indicated for the treatment of pain in Ontario.
2.4. Statistical analysis
We used conditional logistic regression to estimate odds ratios and
95% conﬁdence intervals for the association between opioid-related
death and receipt of benzodiazepines, antidepressants or antipsychotics
in the preceding year. A secondary analysis examined the association for
each of these classes individually. We adjusted all models for other
medication exposures (other opioids, QT prolonging drugs, barbiturates
and anticonvulsants), aswell as for other potential risk factors including
baseline characteristics (age, sex, and rural vs. urban place of residence),
health service utilization (number of visits to amethadone prescriber in
past 2months, number of urine drug screens in the past 1 year, any ECG
in the past year, and initiation of methadone 30 days prior to the index
date), and comorbidities (Johns Hopkins adjusted clinical groups
(Weiner, 2003)) in previous year, and diagnoses of chronic lung disease,
sleep apnea, alcohol use disorder, chronic liver disease, mood disorder,
psychosis/schizophrenia, and heart disease (coronary artery disease or
arrhythmia). All analyses used a two-sided type I error rate of 0.05 as
the threshold for statistical signiﬁcance and were performed using SAS
version 9.3 (SAS Institute, Cary, North Carolina).
3. Results
During the 16-year study period, we identiﬁed 43,545 patients receiv-
ingmethadone for an opioid use disorder. After exclusions, 175 died of an
opioid-related cause and were matched to 873 matched controls. The
characteristics of case and control subjects are shown in Table 1. The
median age of case patients was 42 years (IQR 36 to 48), and 62% were
men. Co-prescription of psychotropic medications and other opioids
was frequent. As expected, compared with controls, case patients were
more likely to have various comorbidities and to have initiated
methadone treatment in the 30 days preceding the index date (Table 1).
In the primary analysis, receipt of any prescription for benzodiaze-
pines, antidepressants, or antipsychotic drug in the past year was asso-
ciated with a twofold increase in the risk of opioid-related death
(adjusted odds ratio 2.0; 95% conﬁdence interval 1.2 to 3.5) (Table 2).
In the secondary analysis of individual drug classes, we found that
benzodiazepines (adjusted OR 1.6; 95% CI 1.1 to 2.5) and antipsychotics
(adjusted OR 2.3; 95% CI 1.5 to 3.5) remained independently associated
with opioid-related death during methadone therapy, while
antidepressants did not (Table 2).
We also found associations between chronic lung disease, alcohol
use disorders, mood disorders, heart disease (coronary disease or ar-
rhythmia disorders), and initiation of methadone in the 30 days prior
to death and opioid-related death (Table 3). We did not ﬁnd associa-
tions between opioid-related death and co-prescription of individual
opioids, barbiturates, anticonvulsants, or QT-prolonging drugs. Further,
we did not ﬁnd associations with number of visits to a methadone pre-
scriber, number of urine drug screens, a prior ECG, chronic liver disease
or schizophrenia and opioid-related death.
4. Discussion
In this population-based study spanning 16 years, we found that
amongmethadone recipients psychotropic drug prescribingwas associat-
ed with a two fold increased risk of opioid-related death. We also found
that several other comorbidities were associated with an increased risk
of opioid-related death among methadone recipients, as was initiation
of methadone treatment in the past 30 days. Our study extends the
literature by further characterizing the inﬂuence of concurrentprescriptions and co-morbid conditions on opioid-related deaths among
individuals receiving methadone treatment for an opioid use disorder.
Our ﬁndings conﬁrm some previous ﬁndings, and also address
several challenges identiﬁed in the most recent systematic review of
this topic (Weimer & Chou, 2014). Our ﬁndings reafﬁrm the increased
risk of mortality during methadone initiation (Degenhardt et al., 2009;
Srivastava & Kahan, 2006), as well as the high prevalence of, and risks
associated with, benzodiazepine prescribing among patients receiving
methadone (Chou, Weimer and Dana, 2014; Cousins et al., 2011;
McCowan et al., 2009). Recently, others have called for a better under-
standing of the mortality risk during methadone maintenance treat-
ment associated with medical comorbidities and drug interactions
(Weimer & Chou, 2014).
Unlike previous studies, we did not ﬁnd an association between an-
tidepressant use and opioid-related mortality (Chan et al., 2006;
Weimer et al., 2011). One previous cohort paradoxically found that an-
tipsychotic drugs and antidepressants were protective (McCowan et al.,
Table 2
Medications in the prior year associated with opioid-related death during methadone
maintenance therapy.
Medication Unadjusted odds ratio
(95% conﬁdence interval
Adjusted odds ratioa
(95% conﬁdence
interval)
Primary analysis
Benzodiazepines,
antidepressants, and/or
antipsychotics
2.88 (1.78 to 4.64) 2.02 (1.18 to 3.47)
Secondary analyses
Benzodiazepines 1.93 (1.33 to 2.80) 1.64 (1.09 to 2.46)
Antidepressants 1.35 (0.91 to 1.99) 1.22 (0.80 to 1.88)
Antipsychotics 2.46 (1.72 to 3.54) 2.32 (1.54 to 3.48)
Opioids 1.70 (1.22 to 2.35) 0.95 (0.64 to 1.42)
Long-acting oxycodone 0.59 (0.29 to 1.20) 0.53 (0.25 to 1.11)
Codeine 1.37 (0.96 to 2.01) 1.12 (0.74 to 1.68)
Morphine 0.69 (0.34 to 1.42) 0.80 (0.37 to 1.70)
Hydromorphone 1.52 (0.72 to 3.23) 1.18 (0.51 to 2.73)
Fentanyl 2.49 (0.84 to 7.37) 1.60 (0.48 to 5.43)
Meripidine/Penthidine 0.74 (0.15 to 3.70) 0.88 (0.16 to 4.73)
Barbiturates 1.84 (0.11 to 31.98) 2.30 (0.11 to 48.80)
Anticonvulsants 2.02 (1.11 to 3.70) 1.65 (0.86 to 3.18)
QT prolonging drugsb 1.32 (0.91 to 1.91) 1.06 (0.70 to 1.60)
a Adjusted formedication exposures, aswell as for other potential risk factors including
baseline characteristics (age, sex, and rural vs. urban place of residence), health service uti-
lization (number of visits to a methadone prescriber in past 2 months, urine drug screens
in the past 1 year, ECG in the past 1 year, and initiation of methadone 30 days prior to the
index date), and comorbidities (Johns Hopkins adjusted clinical groups in previous year,
and diagnoses of chronic lung disease, sleep apnea, alcohol use disorder, chronic liver dis-
ease,mooddisorder, psychosis/schizophrenia, and coronary artery disease or arrhythmia).
b These included alfuzosin, amiodarone, azithromycin, chloroquine, ciproﬂoxacin,
clarithromycin, crizotinib, cyclobenzaprine, dasatinib, disopyramide, dolasetron, erythro-
mycin, ﬂecainide, granisetron, lapatinib, levoﬂoxacin, ritonavir, moxiﬂoxacin, nilotinib,
norﬂoxacin, ondansetron, pazopanib, pentamidine, procainamide, propafenone, quini-
dine, saquinavir, solifenacin, sotalol, sunitinib, tacrolimus, telithromycin, tetrabenazine.
Table 3
Characteristics associated with opioid-related death duringmethadonemaintenance therapy.
Characteristic Unadjusted odds ratio
(95% conﬁdence
interval)
Adjusted odds ratioa
(95% conﬁdence
interval)
Age 1.04 (1.02 to 1.06) 1.02 (1.00 to 1.04)
Male 1.00 (0.72 to 1.40) 1.20 (0.81 to 1.78)
Rural 0.46 (2.01 to 1.02) 0.74 (0.32 to 1.76)
Number of visits to a
methadone prescriberb
1.01 (0.98 to 1.00) 0.99 (0.95 to 1.03)
Number of urine drug testsc 0.99 (0.99 to 1.00) 1.00 (0.99 to 1.01)
ECGc 2.15 (1.54 to 3.00) 1.10 (0.72 to 1.67)
Initiation of methadone in
the 30 days prior to index
date
9.41 (3.11 to 28.44) 15.19(4.40 to 52.46)
John Hopkins ACGc
0–4 1.00 (reference) 1.00 (reference)
5–9 1.79 (1.19 to 2.69) 1.06 (0.66 to 1.69)
10–14 4.60 (2.94 to 7.20) 1.58 (0.85 to 2.93)
15–19 7.67 (3.14 to 18.74) 1.78 (0.59 to 5.40)
Chronic lung diseasec 2.51 (1.80 to 3.49) 1.74 (1.16 to 2.60)
Alcohol use disorderc 3.46 (2.27 to 5.28) 1.95 (1.18 to 3.23)
Chronic liver diseasec 1.82 (1.22 to 2.72) 1.19 (0.74 to 1.92)
Heart disease (coronary
artery disease or
arrhythmia)c
9.66 (4.20 to 22.24) 5.32 (2.03 to 13.95)
Mood disordersc 3.46 (2.16 to 5.56) 1.80 (1.00 to 3.24)
Schizophreniac 0.71 (0.09 to 5.82) 0.21 (0.02 to 2.02)
a Adjusted formedication exposures, aswell as for other potential risk factors including
baseline characteristics (age, sex, and rural vs. urban place of residence), health service uti-
lization (number of visits to a methadone prescriber in past 2 months, urine drug screens
in the past 1 year, ECG in the past 1 year and initiation of methadone 30 days prior to the
index date), and comorbidities (Johns Hopkins adjusted clinical groups in previous year,
and diagnoses of chronic lung disease, sleep apnea, alcohol use disorder, chronic liver dis-
ease,mooddisorder, psychosis/schizophrenia, and coronary artery disease or arrhythmia).
b In the 2 months prior to the index event.
c In the 1 year prior to the index date.
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and opioid-related mortality. The high number of patients using anti-
psychotics comparedwith those diagnosedwith schizophrenia suggests
frequent use of antipsychotics for other indications.
Previous research found pulmonary and hepatic disease common
among coroners' cases of opioid toxicity (Darke et al., 2006), and cau-
tion is typically advised when considering methadone prescriptions
among individuals with respiratory illness or heavy alcohol consump-
tion (Hillier, 2011). Our ﬁndings provide further support for lung
disease and alcohol use disorder as independent risk factors for
opioid-related death during methadone treatment. Accordingly, pa-
tients on methadone treatment should also be assessed for these risk
factors and counseled about alcohol use. The identiﬁcation of alcohol
use is especially important in light of relevant literature indicating that
alcohol intake does not decline during methadone maintenance treat-
ment (Srivastava, Kahan, & Ross, 2008).
Previous research has also described cardiac pathology among cases
of death due to opioid toxicity (Darke et al., 2006). However, ourﬁnding
that heart disease was speciﬁcally associated with opioid-related death
among patients prescribed methadone for an opioid use disorder is
novel. This ﬁnding may reﬂect the known effects of methadone on the
QT interval (Chou, Weimer and Dana, 2014). However, our ﬁndings
that performance of an ECG andQT-prolonging drugswere not associat-
ed with opioid-related mortality suggest that not all cardiac risks are
identiﬁable using ECG results alone.
Several implications of these ﬁndings for methadone prescribers are
worth noting. Patients with co-occurring alcohol use disorders or heart
disease should be monitored closely. Further, caution is advised when
prescribing antipsychotics unless clearly indicated. The lack of association
with urine drug screening in our study merits further study, as drug
testing represents a large cost duringmethadonemaintenance treatment.
In contrast to themajority of literature onmortality related tometh-
adone (Bernard et al., 2013; Chan et al., 2006; Cousins et al., 2011;
McCowan et al., 2009; Pilgrim et al., 2013; The DAWN Report, 2004;
Zador & Sunjic, 2000) we focused on opioid-related mortality among
patients prescribed methadone for an opioid use disorder because the
most frequent cause of death among individuals onmethadone therapy
is drug-related (McCowan et al., 2009; Zador & Sunjic, 2000). The
existing literature suggests that the majority of deaths associated with
methadone involve illicit use of the drug or use for the treatment of
pain (“Vital signs: risk for overdose frommethadone used for pain relief
- United States, 1999-2010.,” 2012; Wikner et al., 2014).
Some limitations of our studymerit emphasis. First, our prescription
data are limited to patients receiving social assistance, and whether
these ﬁndings apply to more afﬂuent patients is unknown. Second, we
used administrative data and had no information regardingmethadone
adherence, doses of medications and use of nonprescription drugs. We
also could not identify which patients received take-home doses of
methadone. As expected in a case-control study, cases and controls dif-
fered substantially on several important characteristics. Finally, we
could not ascertain the contributions of QTprolongation and respiratory
depression among these deaths.
In summary, we found that the use of psychotropic drugs as well as
an alcohol use disorder, lung and heart disease, mood disorders, and the
recent initiation ofmethadonewas a factor associatedwith an increased
risk of opioid-relatedmortality amongpatients receivingmethadone for
an opioid use disorder. Mindfulness of comorbidities and drug interac-
tions, particularly those involving psychotropic medications, could re-
duce the risk of opioid-related death among patients on methadone.
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